Ancillary 0 9 0 9 B-treatment
cPoP 10 14 10 14 I-treatment
Part 15 19 15 19 O
: 19 20 19 20 O
any 21 24 21 24 O
tumor 25 30 25 30 B-cancer
with 31 35 31 35 O
at 36 38 36 38 O
least 39 44 39 44 O
2 45 46 45 46 B-lower_bound
( 47 48 47 48 B-cancer
sub)cutaneous 48 61 48 61 I-cancer
tumor 62 67 62 67 I-cancer
/ 67 68 67 68 O
metastases 68 78 68 78 B-cancer
at 79 81 79 81 O
least 82 87 82 87 O
2 88 89 88 89 B-lower_bound
cm 90 92 90 92 I-lower_bound
apart 93 98 93 98 O
which 99 104 99 104 O
are 105 108 105 108 O
RT 109 111 109 111 O
naïve 112 117 112 117 O
with 118 122 118 122 O
an 123 125 123 125 O
indication 126 136 126 136 O
for 137 140 137 140 O
high 141 145 141 145 O
dose 146 150 146 150 O
palliative 151 161 151 161 B-treatment
RT 162 164 162 164 I-treatment

Bone 0 4 165 169 B-chronic_disease
marrow 5 11 170 176 I-chronic_disease
impairment 12 22 177 187 I-chronic_disease
as 23 25 188 190 O
evidenced 26 35 191 200 O
by 36 38 201 203 O
hemoglobin 39 49 204 214 B-clinical_variable
< 50 51 215 216 O
10.0 51 55 216 220 B-upper_bound
g 56 57 221 222 I-upper_bound
/ 57 58 222 223 I-upper_bound
dL 58 60 223 225 I-upper_bound
, 60 61 225 226 O
neutrophil 62 72 227 237 B-clinical_variable
count 73 78 238 243 I-clinical_variable
< 79 80 244 245 O
1.0 80 83 245 248 B-upper_bound
× 84 85 249 250 I-upper_bound
109 86 89 251 254 I-upper_bound
/ 89 90 254 255 I-upper_bound
L 90 91 255 256 I-upper_bound
, 91 92 256 257 O
platelets 93 102 258 267 B-clinical_variable
< 103 104 268 269 O
100 104 107 269 272 B-upper_bound
× 108 109 273 274 I-upper_bound
109 110 113 275 278 I-upper_bound
/ 113 114 278 279 I-upper_bound
L 114 115 279 280 I-upper_bound

Eastern 0 7 281 288 B-clinical_variable
Cooperative 8 19 289 300 I-clinical_variable
Oncology 20 28 301 309 I-clinical_variable
Group 29 34 310 315 I-clinical_variable
performance 35 46 316 327 I-clinical_variable
status 47 53 328 334 I-clinical_variable
( 54 55 335 336 I-clinical_variable
ECOG 55 59 336 340 I-clinical_variable
PS 60 62 341 343 I-clinical_variable
) 62 63 343 344 I-clinical_variable
≤ 64 65 345 346 O
1 66 67 347 348 B-upper_bound

Extensive 0 9 349 358 O
prior 10 15 359 364 B-treatment
RT 16 18 365 367 I-treatment
on 19 21 368 370 O
≥30 22 25 371 374 O
% 25 26 374 375 I-lower_bound
of 27 29 376 378 O
bone 30 34 379 383 B-clinical_variable
marrow 35 41 384 390 I-clinical_variable
reserve 42 49 391 398 O
as 50 52 399 401 O
judged 53 59 402 408 O
by 60 62 409 411 O
the 63 66 412 415 O
investigator 67 79 416 428 O
or 80 82 429 431 O
prior 83 88 432 437 B-treatment
bone 89 93 438 442 I-treatment
marrow 94 100 443 449 I-treatment
/ 100 101 449 450 O
stem 101 105 450 454 B-treatment
cell 106 110 455 459 I-treatment
transplantation 111 126 460 475 I-treatment
within 127 133 476 482 O
5 134 135 483 484 B-upper_bound
years 136 141 485 490 I-upper_bound
before 142 148 491 497 I-upper_bound
trial 149 154 498 503 O
start 155 160 504 509 O

Female 0 6 510 516 B-gender
subjects 7 15 517 525 I-gender
of 16 18 526 528 O
childbearing 19 31 529 541 O
potential 32 41 542 551 O
and 42 45 552 555 O
male 46 50 556 560 O
subjects 51 59 561 569 O
with 60 64 570 574 O
female 65 71 575 581 B-gender
partners 72 80 582 590 I-gender
of 81 83 591 593 O
childbearing 84 96 594 606 O
potential 97 106 607 616 O
must 107 111 617 621 O
be 112 114 622 624 O
willing 115 122 625 632 O
to 123 125 633 635 O
avoid 126 131 636 641 O
pregnancy 132 141 642 651 B-pregnancy

History 0 7 652 659 O
of 8 10 660 662 O
any 11 14 663 666 O
other 15 20 667 672 O
significant 21 32 673 684 O
medical 33 40 685 692 O
disease 41 48 693 700 O
such 49 53 701 705 O
as 54 56 706 708 O
major 57 62 709 714 B-treatment
gastric 63 70 715 722 I-treatment
or 71 73 723 725 O
small 74 79 726 731 B-treatment
bowel 80 85 732 737 I-treatment
surgery 86 93 738 745 I-treatment
, 93 94 745 746 O
recent 95 101 747 753 O
drainage 102 110 754 762 B-treatment
of 111 113 763 765 I-treatment
significant 114 125 766 777 I-treatment
volumes 126 133 778 785 I-treatment
of 134 136 786 788 I-treatment
ascites 137 144 789 796 I-treatment
or 145 147 797 799 O
pleural 148 155 800 807 B-chronic_disease
effusion 156 164 808 816 I-chronic_disease
( 165 166 817 818 O
as 166 168 818 820 O
per 169 172 821 824 O
Investigator 173 185 825 837 O
's 185 187 837 839 O
judgement 188 197 840 849 O
) 197 198 849 850 O
or 199 201 851 853 O
a 202 203 854 855 O
psychiatric 204 215 856 867 O
condition 216 225 868 877 O
that 226 230 878 882 O
might 231 236 883 888 O
impair 237 243 889 895 O
the 244 247 896 899 O
subject 248 255 900 907 O
's 255 257 907 909 O
well 258 262 910 914 O
- 262 263 914 915 O
being 263 268 915 920 O
or 269 271 921 923 O
preclude 272 280 924 932 O
full 281 285 933 937 O
participation 286 299 938 951 O
in 300 302 952 954 O
the 303 306 955 958 O
trial 307 312 959 964 O

History 0 7 965 972 O
of 8 10 973 975 O
difficulty 11 21 976 986 O
swallowing 22 32 987 997 O
, 32 33 997 998 O
malabsorption 34 47 999 1012 O
or 48 50 1013 1015 O
other 51 56 1016 1021 O
chronic 57 64 1022 1029 O
gastrointestinal 65 81 1030 1046 B-chronic_disease
disease 82 89 1047 1054 I-chronic_disease
or 90 92 1055 1057 O
conditions 93 103 1058 1068 O
that 104 108 1069 1073 O
may 109 112 1074 1077 O
hamper 113 119 1078 1084 O
compliance 120 130 1085 1095 O
and/or 131 137 1096 1102 O
absorption 138 148 1103 1113 O
of 149 151 1114 1116 O
the 152 155 1117 1120 O
IMP 156 159 1121 1124 B-treatment

History 0 7 1125 1132 O
of 8 10 1133 1135 O
difficulty 11 21 1136 1146 O
swallowing 22 32 1147 1157 O
, 32 33 1157 1158 O
malabsorption 34 47 1159 1172 B-chronic_disease
or 48 50 1173 1175 O
other 51 56 1176 1181 O
chronic 57 64 1182 1189 O
gastrointestinal 65 81 1190 1206 B-chronic_disease
disease 82 89 1207 1214 I-chronic_disease
or 90 92 1215 1217 O
conditions 93 103 1218 1228 O
that 104 108 1229 1233 O
may 109 112 1234 1237 O
hamper 113 119 1238 1244 O
compliance 120 130 1245 1255 O
and/or 131 137 1256 1262 O
absorption 138 148 1263 1273 O
of 149 151 1274 1276 O
the 152 155 1277 1280 O
IMP 156 159 1281 1284 B-treatment
, 159 160 1284 1285 O
use 161 164 1286 1289 O
of 165 167 1290 1292 O
percutaneous 168 180 1293 1305 B-treatment
endoscopic 181 191 1306 1316 I-treatment
gastrostomy 192 203 1317 1328 I-treatment
( 204 205 1329 1330 I-treatment
PEG 205 208 1330 1333 I-treatment
) 208 209 1333 1334 I-treatment
tubes 210 215 1335 1340 I-treatment

Life 0 4 1341 1345 B-clinical_variable
expectancy 5 15 1346 1356 I-clinical_variable
of 16 18 1357 1359 O
≥ 19 20 1360 1361 O
3 21 22 1362 1363 B-lower_bound
months 23 29 1364 1370 I-lower_bound
( 30 31 1371 1372 O
Phase 31 36 1372 1377 B-clinical_variable
Ia 37 39 1378 1380 I-clinical_variable
, 39 40 1380 1381 I-clinical_variable
Arm 41 44 1382 1385 I-clinical_variable
A 45 46 1386 1387 I-clinical_variable
) 46 47 1387 1388 O
or 48 50 1389 1391 O
≥ 51 52 1392 1393 O
6 53 54 1394 1395 B-lower_bound
months 55 61 1396 1402 I-lower_bound
( 62 63 1403 1404 O
Phase 63 68 1404 1409 B-clinical_variable
Ia 69 71 1410 1412 I-clinical_variable
, 71 72 1412 1413 I-clinical_variable
Arm 73 76 1414 1417 I-clinical_variable
B 77 78 1418 1419 I-clinical_variable
and 79 82 1420 1423 I-clinical_variable
Phase 83 88 1424 1429 I-clinical_variable
Ib 89 91 1430 1432 I-clinical_variable
) 91 92 1432 1433 O

Liver 0 5 1434 1439 O
function 6 14 1440 1448 O
abnormality 15 26 1449 1460 O
as 27 29 1461 1463 O
defined 30 37 1464 1471 O
by 38 40 1472 1474 O
total 41 46 1475 1480 B-clinical_variable
bilirubin 47 56 1481 1490 I-clinical_variable
> 57 58 1491 1492 O
1.5 58 61 1492 1495 B-lower_bound
× 62 63 1496 1497 I-lower_bound
ULN 64 67 1498 1501 I-lower_bound
or 68 70 1502 1504 O
aspartate 71 80 1505 1514 B-clinical_variable
aminotransferase 81 97 1515 1531 I-clinical_variable
( 98 99 1532 1533 I-clinical_variable
AST)/alanine 99 111 1533 1545 I-clinical_variable
aminotransferase 112 128 1546 1562 I-clinical_variable
( 129 130 1563 1564 I-clinical_variable
ALT 130 133 1564 1567 I-clinical_variable
) 133 134 1567 1568 I-clinical_variable
> 135 136 1569 1570 O
2.5 136 139 1570 1573 B-lower_bound
× 140 141 1574 1575 I-lower_bound
ULN 142 145 1576 1579 I-lower_bound
( 146 147 1580 1581 O
except 147 153 1581 1587 O
for 154 157 1588 1591 O
subjects 158 166 1592 1600 O
with 167 171 1601 1605 O
liver 172 177 1606 1611 O
involvement 178 189 1612 1623 O
, 189 190 1623 1624 O
who 191 194 1625 1628 O
can 195 198 1629 1632 O
have 199 203 1633 1637 O
AST 204 207 1638 1641 B-clinical_variable
/ 207 208 1641 1642 I-clinical_variable
ALT 208 211 1642 1645 I-clinical_variable
> 212 213 1646 1647 O
5 213 214 1647 1648 O
× 215 216 1649 1650 O
ULN 217 220 1651 1654 O
) 220 221 1654 1655 O

Measurable 0 10 1656 1666 O
or 11 13 1667 1669 O
evaluable 14 23 1670 1679 O
disease 24 31 1680 1687 O
by 32 34 1688 1690 O
RECIST 35 41 1691 1697 O
v1.1 42 46 1698 1702 O
( 47 48 1703 1704 O
not 48 51 1704 1707 O
required 52 60 1708 1716 O
for 61 64 1717 1720 O
ancillary 65 74 1721 1730 B-treatment
cPoP 75 79 1731 1735 I-treatment
part 80 84 1736 1740 O
of 85 87 1741 1743 O
the 88 91 1744 1747 O
study 92 97 1748 1753 O
) 97 98 1753 1754 O

Phase 0 5 1755 1760 O
Ia 6 8 1761 1763 O
part 9 13 1764 1768 O
: 13 14 1768 1769 O
advanced 15 23 1770 1778 O
solid 24 29 1779 1784 B-cancer
tumors 30 36 1785 1791 I-cancer
or 37 39 1792 1794 O
metastases 40 50 1795 1805 B-cancer
including 51 60 1806 1815 O
lymphoma 61 69 1816 1824 B-cancer
localized 70 79 1825 1834 O
in 80 82 1835 1837 O
the 83 86 1838 1841 O
head 87 91 1842 1846 O
and 92 95 1847 1850 O
neck 96 100 1851 1855 O
region 101 107 1856 1862 O
or 108 110 1863 1865 O
thorax 111 117 1866 1872 O
with 118 122 1873 1877 O
an 123 125 1878 1880 O
indication 126 136 1881 1891 O
for 137 140 1892 1895 O
fractionated 141 153 1896 1908 O
palliative 154 164 1909 1919 O
RT 165 167 1920 1922 B-treatment
( 168 169 1923 1924 O
Arm 169 172 1924 1927 O
A 173 174 1928 1929 O
) 174 175 1929 1930 O
; 175 176 1930 1931 O
or 177 179 1932 1934 O
treatment 180 189 1935 1944 B-treatment
- 189 190 1944 1945 O
naïve 190 195 1945 1950 O
SCCHN 196 201 1951 1956 B-cancer
eligible 202 210 1957 1965 O
for 211 214 1966 1969 O
fractionated 215 227 1970 1982 O
curatively 228 238 1983 1993 O
intended 239 247 1994 2002 O
RT 248 250 2003 2005 O
with 251 255 2006 2010 O
concurrent 256 266 2011 2021 O
cisplatin 267 276 2022 2031 B-treatment
( 277 278 2032 2033 O
Arm 278 281 2033 2036 O
B 282 283 2037 2038 O
) 283 284 2038 2039 O

Phase 0 5 2040 2045 O
Ib 6 8 2046 2048 O
part 9 13 2049 2053 O
: 13 14 2053 2054 O
treatment 15 24 2055 2064 B-treatment
- 24 25 2064 2065 O
naïve 25 30 2065 2070 O
Stage 31 36 2071 2076 O
III 37 40 2077 2080 O
A 41 42 2081 2082 O
/ 42 43 2082 2083 O
B 43 44 2083 2084 O
NSCLC 45 50 2085 2090 B-cancer
not 51 54 2091 2094 O
eligible 55 63 2095 2103 O
for 64 67 2104 2107 O
surgical 68 76 2108 2116 B-treatment
resection 77 86 2117 2126 I-treatment
or 87 89 2127 2129 O
concurrent 90 100 2130 2140 O
chemoradiation 101 115 2141 2155 B-treatment
( 116 117 2156 2157 O
Arm 117 120 2157 2160 O
A 121 122 2161 2162 O
expansion 123 132 2163 2172 O
cohort 133 139 2173 2179 O
) 139 140 2179 2180 O
or 141 143 2181 2183 O
treatment 144 153 2184 2193 O
- 153 154 2193 2194 O
naïve 154 159 2194 2199 O
SCCHN 160 165 2200 2205 B-cancer
eligible 166 174 2206 2214 O
for 175 178 2215 2218 O
fractionated 179 191 2219 2231 O
curatively 192 202 2232 2242 O
intended 203 211 2243 2251 O
RT 212 214 2252 2254 O
with 215 219 2255 2259 O
concurrent 220 230 2260 2270 O
cisplatin 231 240 2271 2280 B-treatment
( 241 242 2281 2282 O
Arm 242 245 2282 2285 O
B 246 247 2286 2287 O
expansion 248 257 2288 2297 O
cohort 258 264 2298 2304 O
) 264 265 2304 2305 O

Prior 0 5 2306 2311 B-treatment
RT 6 8 2312 2314 I-treatment
to 9 11 2315 2317 O
the 12 15 2318 2321 O
same 16 20 2322 2326 O
region 21 27 2327 2333 O
within 28 34 2334 2340 O
12 35 37 2341 2343 B-upper_bound
months 38 44 2344 2350 I-upper_bound
( 45 46 2351 2352 O
Phase 46 51 2352 2357 O
Ia 52 54 2358 2360 O
, 54 55 2360 2361 O
Arm 56 59 2362 2365 O
A 60 61 2366 2367 O
; 61 62 2367 2368 O
subjects 63 71 2369 2377 O
with 72 76 2378 2382 O
tumors 77 83 2383 2389 B-cancer
localized 84 93 2390 2399 O
in 94 96 2400 2402 O
the 97 100 2403 2406 O
head 101 105 2407 2411 O
and 106 109 2412 2415 O
neck 110 114 2416 2420 O
region 115 121 2421 2427 O
or 122 124 2428 2430 O
thorax 125 131 2431 2437 O
) 131 132 2437 2438 O
or 133 135 2439 2441 O
at 136 138 2442 2444 O
any 139 142 2445 2448 O
time 143 147 2449 2453 O
previously 148 158 2454 2464 O
( 159 160 2465 2466 O
Phase 160 165 2466 2471 O
Ia 166 168 2472 2474 O
, 168 169 2474 2475 O
Arm 170 173 2476 2479 O
B 174 175 2480 2481 O
; 175 176 2481 2482 O
treatment 177 186 2483 2492 B-treatment
- 186 187 2492 2493 O
naïve 187 192 2493 2498 O
subjects 193 201 2499 2507 O
with 202 206 2508 2512 O
SCCHN 207 212 2513 2518 B-cancer
and 213 216 2519 2522 O
Phase 217 222 2523 2528 O
Ib 223 225 2529 2531 O
; 225 226 2531 2532 O
treatment 227 236 2533 2542 O
- 236 237 2542 2543 O
naïve 237 242 2543 2548 O
subjects 243 251 2549 2557 O
with 252 256 2558 2562 O
Stage 257 262 2563 2568 B-cancer
III 263 266 2569 2572 I-cancer
A 267 268 2573 2574 I-cancer
/ 268 269 2574 2575 I-cancer
B 269 270 2575 2576 I-cancer
NSCLC 271 276 2577 2582 I-cancer
or 277 279 2583 2585 O
SCCHN 280 285 2586 2591 O
) 285 286 2591 2592 O

Renal 0 5 2593 2598 B-chronic_disease
impairment 6 16 2599 2609 I-chronic_disease
as 17 19 2610 2612 O
evidenced 20 29 2613 2622 O
by 30 32 2623 2625 O
serum 33 38 2626 2631 B-clinical_variable
creatinine 39 49 2632 2642 I-clinical_variable
> 50 51 2643 2644 O
1.5 51 54 2644 2647 B-lower_bound
× 55 56 2648 2649 I-lower_bound
upper 57 62 2650 2655 I-lower_bound
limit 63 68 2656 2661 I-lower_bound
of 69 71 2662 2664 I-lower_bound
normal 72 78 2665 2671 I-lower_bound
( 79 80 2672 2673 I-lower_bound
ULN 80 83 2673 2676 I-lower_bound
) 83 84 2676 2677 I-lower_bound

Significant 0 11 2678 2689 O
cardiac 12 19 2690 2697 B-chronic_disease
conduction 20 30 2698 2708 I-chronic_disease
abnormalities 31 44 2709 2722 I-chronic_disease
, 44 45 2722 2723 O
including 46 55 2724 2733 O
a 56 57 2734 2735 O
history 58 65 2736 2743 O
of 66 68 2744 2746 O
long 69 73 2747 2751 B-chronic_disease
QTc 74 77 2752 2755 I-chronic_disease
syndrome 78 86 2756 2764 I-chronic_disease
and/or 87 93 2765 2771 O
pacemaker 94 103 2772 2781 O
, 103 104 2781 2782 O
or 105 107 2783 2785 O
impaired 108 116 2786 2794 B-chronic_disease
cardiovascular 117 131 2795 2809 I-chronic_disease
function 132 140 2810 2818 I-chronic_disease
such 141 145 2819 2823 O
as 146 148 2824 2826 O
New 149 152 2827 2830 B-clinical_variable
York 153 157 2831 2835 I-clinical_variable
Heart 158 163 2836 2841 I-clinical_variable
Association 164 175 2842 2853 I-clinical_variable
classification 176 190 2854 2868 I-clinical_variable
score 191 196 2869 2874 I-clinical_variable
> 197 198 2875 2876 O
2 198 199 2876 2877 B-lower_bound

Subjects 0 8 2878 2886 O
currently 9 18 2887 2896 O
receiving 19 28 2897 2906 O
( 29 30 2907 2908 O
or 30 32 2908 2910 O
unable 33 39 2911 2917 O
to 40 42 2918 2920 O
stop 43 47 2921 2925 O
using 48 53 2926 2931 O
prior 54 59 2932 2937 O
to 60 62 2938 2940 O
receiving 63 72 2941 2950 O
the 73 76 2951 2954 O
first 77 82 2955 2960 O
dose 83 87 2961 2965 O
of 88 90 2966 2968 O
study 91 96 2969 2974 B-treatment
drug 97 101 2975 2979 I-treatment
) 101 102 2979 2980 O
medications 103 114 2981 2992 B-treatment
or 115 117 2993 2995 O
herbal 118 124 2996 3002 B-treatment
supplements 125 136 3003 3014 I-treatment
known 137 142 3015 3020 O
to 143 145 3021 3023 O
be 146 148 3024 3026 O
potent 149 155 3027 3033 B-treatment
inhibitors 156 166 3034 3044 I-treatment
of 167 169 3045 3047 I-treatment
CYP3A 170 175 3048 3053 I-treatment
or 176 178 3054 3056 O
CYP2C19 179 186 3057 3064 B-treatment
must 187 191 3065 3069 O
stop 192 196 3070 3074 O
at 197 199 3075 3077 O
least 200 205 3078 3083 O
1 206 207 3084 3085 B-lower_bound
week 208 212 3086 3090 I-lower_bound
prior 213 218 3091 3096 I-lower_bound
to 219 221 3097 3099 O
taking 222 228 3100 3106 O
MSC2490484A. 229 241 3107 3119 B-treatment
Subjects 242 250 3120 3128 O
receiving 251 260 3129 3138 O
potent 261 267 3139 3145 B-treatment
inducers 268 276 3146 3154 I-treatment
of 277 279 3155 3157 I-treatment
CYP3A 280 285 3158 3163 I-treatment
or 286 288 3164 3166 O
CYP2C19 289 296 3167 3174 O
must 297 301 3175 3179 O
stop 302 306 3180 3184 O
at 307 309 3185 3187 O
least 310 315 3188 3193 O
3 316 317 3194 3195 B-lower_bound
weeks 318 323 3196 3201 I-lower_bound
prior 324 329 3202 3207 I-lower_bound
to 330 332 3208 3210 O
taking 333 339 3211 3217 O
MSC2490484A. 340 352 3218 3230 O
Those 353 358 3231 3236 O
receiving 359 368 3237 3246 O
drugs 369 374 3247 3252 O
mainly 375 381 3253 3259 O
metabolized 382 393 3260 3271 O
by 394 396 3272 3274 O
CYP3A 397 402 3275 3280 O
with 403 407 3281 3285 O
a 408 409 3286 3287 O
narrow 410 416 3288 3294 O
therapeutic 417 428 3295 3306 O
index 429 434 3307 3312 O
as 435 437 3313 3315 O
judged 438 444 3316 3322 O
by 445 447 3323 3325 O
the 448 451 3326 3329 O
Investigator 452 464 3330 3342 O
( 465 466 3343 3344 O
and 466 469 3344 3347 O
after 470 475 3348 3353 O
optional 476 484 3354 3362 O
consultation 485 497 3363 3375 O
with 498 502 3376 3380 O
the 503 506 3381 3384 O
Sponsor 507 514 3385 3392 O
) 514 515 3392 3393 O
must 516 520 3394 3398 O
stop 521 525 3399 3403 O
at 526 528 3404 3406 O
least 529 534 3407 3412 O
one 535 538 3413 3416 B-lower_bound
day 539 542 3417 3420 I-lower_bound
prior 543 548 3421 3426 I-lower_bound
to 549 551 3427 3429 O
taking 552 558 3430 3436 O
MSC2490484A 559 570 3437 3448 O

Subjects 0 8 3449 3457 O
currently 9 18 3458 3467 O
receiving 19 28 3468 3477 O
( 29 30 3478 3479 O
or 30 32 3479 3481 O
unable 33 39 3482 3488 O
to 40 42 3489 3491 O
stop 43 47 3492 3496 O
using 48 53 3497 3502 O
prior 54 59 3503 3508 O
to 60 62 3509 3511 O
receiving 63 72 3512 3521 O
the 73 76 3522 3525 O
first 77 82 3526 3531 O
dose 83 87 3532 3536 O
of 88 90 3537 3539 O
trial 91 96 3540 3545 O
drug 97 101 3546 3550 O
) 101 102 3550 3551 O
medications 103 114 3552 3563 B-treatment
or 115 117 3564 3566 O
herbal 118 124 3567 3573 B-treatment
supplements 125 136 3574 3585 I-treatment
known 137 142 3586 3591 O
to 143 145 3592 3594 O
be 146 148 3595 3597 O
potent 149 155 3598 3604 O
inhibitors 156 166 3605 3615 O
of 167 169 3616 3618 O
cytochrome 170 180 3619 3629 B-treatment
P450 181 185 3630 3634 I-treatment
( 186 187 3635 3636 B-treatment
CYP)3A 187 193 3636 3642 I-treatment
or 194 196 3643 3645 O
CYP2C19 197 204 3646 3653 B-treatment
( 205 206 3654 3655 O
must 206 210 3655 3659 O
stop 211 215 3660 3664 O
at 216 218 3665 3667 O
least 219 224 3668 3673 O
1 225 226 3674 3675 B-lower_bound
week 227 231 3676 3680 I-lower_bound
prior 232 237 3681 3686 I-lower_bound
) 237 238 3686 3687 O
, 238 239 3687 3688 O
potent 240 246 3689 3695 O
inducers 247 255 3696 3704 O
of 256 258 3705 3707 O
CYP3A 259 264 3708 3713 B-treatment
or 265 267 3714 3716 O
CYP2C19 268 275 3717 3724 O
( 276 277 3725 3726 O
must 277 281 3726 3730 O
stop 282 286 3731 3735 O
at 287 289 3736 3738 O
least 290 295 3739 3744 O
3 296 297 3745 3746 B-lower_bound
weeks 298 303 3747 3752 I-lower_bound
prior 304 309 3753 3758 I-lower_bound
) 309 310 3758 3759 O
, 310 311 3759 3760 O
or 312 314 3761 3763 O
drugs 315 320 3764 3769 O
mainly 321 327 3770 3776 O
metabolized 328 339 3777 3788 O
by 340 342 3789 3791 O
CYP3A 343 348 3792 3797 B-treatment
with 349 353 3798 3802 I-treatment
a 354 355 3803 3804 I-treatment
narrow 356 362 3805 3811 I-treatment
therapeutic 363 374 3812 3823 I-treatment
index 375 380 3824 3829 I-treatment
( 381 382 3830 3831 O
must 382 386 3831 3835 O
stop 387 391 3836 3840 O
at 392 394 3841 3843 O
least 395 400 3844 3849 O
one 401 404 3850 3853 B-lower_bound
day 405 408 3854 3857 I-lower_bound
prior 409 414 3858 3863 I-lower_bound
) 414 415 3863 3864 O

Subjects 0 8 3865 3873 O
currently 9 18 3874 3883 O
receiving 19 28 3884 3893 O
H2 29 31 3894 3896 B-treatment
- 31 32 3896 3897 I-treatment
blocker 32 39 3897 3904 I-treatment
or 40 42 3905 3907 O
proton 43 49 3908 3914 B-treatment
pump 50 54 3915 3919 I-treatment
inhibitors 55 65 3920 3930 I-treatment
( 66 67 3931 3932 O
or 67 69 3932 3934 O
unable 70 76 3935 3941 O
to 77 79 3942 3944 O
stop 80 84 3945 3949 O
at 85 87 3950 3952 O
least 88 93 3953 3958 O
5 94 95 3959 3960 B-lower_bound
days 96 100 3961 3965 I-lower_bound
prior 101 106 3966 3971 I-lower_bound
to 107 109 3972 3974 O
the 110 113 3975 3978 O
first 114 119 3979 3984 B-treatment
treatment 120 129 3985 3994 I-treatment
) 129 130 3994 3995 O

Subjects 0 8 3996 4004 O
where 9 14 4005 4010 O
more 15 19 4011 4015 O
than 20 24 4016 4020 O
10 25 27 4021 4023 B-lower_bound
% 27 28 4023 4024 I-lower_bound
of 29 31 4025 4027 O
the 32 35 4028 4031 O
total 36 41 4032 4037 B-clinical_variable
esophagus 42 51 4038 4047 I-clinical_variable
volume 52 58 4048 4054 I-clinical_variable
receives 59 67 4055 4063 O
more 68 72 4064 4068 O
than 73 77 4069 4073 O
50 78 80 4074 4076 B-lower_bound
% 80 81 4076 4077 I-lower_bound
of 82 84 4078 4080 O
the 85 88 4081 4084 O
prescribed 89 99 4085 4095 O
RT 100 102 4096 4098 O
dose 103 107 4099 4103 O

Willing 0 7 4104 4111 O
to 8 10 4112 4114 O
have 11 15 4115 4119 O
tumor 16 21 4120 4125 B-cancer
biopsies 22 30 4126 4134 B-treatment
collected 31 40 4135 4144 O
in 41 43 4145 4147 O
Ancillary 44 53 4148 4157 O
cPoP 54 58 4158 4162 O

